Therapeutic Goods Administration says no evidence to link PIP with health risk

The Therapeutic Goods Administration (TGA) in Australia has responded to speculation on health concerns surrounding Poly Implant Prothese (PIP) breast implants, saying there is no evidence to suggest increased risks to health. A panel of experts from the TGA met yesterday to discuss the implications for women who have had such implants and agreed that there was no evidence to support a greater rupture rate in PIP implants compared to other breast implants. In addition they found that there was no adverse effect caused by the chemicals used to make them. TGA national manager Rohan Hammett said: “There is no evidence of cancer-forming chemicals in the implants and there have been no reports to the TGA of the rare cancer, anaplastic large cell lymphoma, associated with PIP implants in Australia.” "The best available expert clinical advice is that there is no current evidence in Australia to support removal of PIP implants in women in whom the implant has not ruptured." Further reports on PIP are expected to be published in the coming days.